Alnylam’s second RNAi approval

Alnylam just won approval for a second drug, givosiran, using its RNAi technology to treat a rare genetic condition called acute hepatic porphyria. The drug, named Givlaari, will be priced at $575,000 per year, with each vial running about $39,000. 

RNA interference works by muting the genes that work improperly and trigger disease. The technology was developed decades ago and even resulted in a Nobel prize, but the first RNAi drug was approved only last year — Alnylam’s patisiran. 

Read more.